Clinical Scorecard: Preoperative Inflammatory-Lymphocyte Recovery Profile and Its Association with Pathological Outcomes in Resected Osteosarcoma: A Retrospective Analysis

At a Glance

Key Highlights

• 54.3% of patients demonstrated poor pathological response.
• Persistent recovery failure was associated with a higher risk of poor pathological response (OR 5.72).
• Tumor necrosis <90% indicates poor response and greater relapse risk.
• The phenotype model produced an AUC of 0.641, lower than the continuous T3 score (AUC 0.665).
• External validation of findings is necessary.

Guideline-Based Recommendations

Diagnosis

• Pathological response assessment post-surgery is critical for evaluating treatment success.

Management

• Neoadjuvant chemotherapy followed by definitive surgery is standard for localized high-grade osteosarcoma.

Monitoring & Follow-up

• Regular assessment of inflammatory-lymphocyte recovery during treatment may provide prognostic information.

Risks

• Tumor necrosis below 90% is associated with increased relapse risk.

Patient & Prescribing Data

Patients diagnosed with osteosarcoma receiving neoadjuvant chemotherapy.

Dynamic changes in inflammatory and lymphocyte recovery may inform prognosis.

Clinical Best Practices

• Utilize peripheral blood biomarkers to assess systemic inflammation and immune reserve.
• Integrate recovery phenotype assessments into clinical evaluations.

Related Resources & Content

• STROBE Statement
• REMARK Guidelines